Recent Updates
Recently added Catalysts

TrenibotulinumtoxinE and OnabotulinumtoxinA

Phase 2

Upper Facial Lines | Small molecule | Other |AbbVie Inc.|Trials Updated: Oct 13, 2026

TrenibotulinumtoxinE and OnabotulinumtoxinA development status

Highest phase Phase 2
Registered trials 1 across 1 sponsor since Oct 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment300

FDA Designations

No designations recorded

TrenibotulinumtoxinE and OnabotulinumtoxinA clinical trials

TrenibotulinumtoxinE and OnabotulinumtoxinA · 1 trial · 2 indications

Phase 2 1
NCT07871513A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With Moderate to Severe Upper Facial LinesUpper Facial Lines
RECRUITING300 Analytics
PHASE2RECRUITING
A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With Moderate to Severe Upper Facial Lines
Upper Facial Lines
NCT07871513300
Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants with Adverse Events (AEs)
Up to Day 150

An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

Percentage of Participants Achieving None or Mild on the Investigator-Assessed Allergan Glabellar Lines Severity Scale (AGLSS)
Day 7

Achievement of None or Mild on the investigator-assessed AGLSS. The AGLSS is a validated 4-point scale (0=None through 3=Severe) used to assess glabellar line severity. A response of None or Mild indicates improvement in glabellar line severity.

Secondary Endpoints

Percentage of Participants Achieving None or Mild on the Subject-Assessed AGLSS
Day 7
Duration Area Under the Curve (AUC) for Time-Averaged Response Based on Achievement of None or Mild on the Investigator-Assessed AGLSS
Up to Day 150
Onset Area Under the Curve (AUC) for Time-Averaged Response Based on Achievement of None or Mild on the Investigator-Assessed AGLSS
Up to to Day 7
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
TrenibotulinumtoxinE/OnabotulinumtoxinA Combination 1EXPERIMENTALParticipants will receive a single treatment of co-reconstituted trenibotulinumtoxinE and onabotulinumtoxinA.
TrenibotulinumtoxinE/OnabotulinumtoxinA Combination 2EXPERIMENTALParticipants will receive a single treatment of co-reconstituted trenibotulinumtoxinE and onabotulinumtoxinA.
TrenibotulinumtoxinE/OnabotulinumtoxinA Combination 3EXPERIMENTALParticipants will receive a single treatment of co-reconstituted trenibotulinumtoxinE and onabotulinumtoxinA.
TrenibotulinumtoxinE/OnabotulinumtoxinA Combination 4EXPERIMENTALParticipants will receive a single treatment of co-reconstituted trenibotulinumtoxinE and onabotulinumtoxinA.
TrenibotulinumtoxinE/OnabotulinumtoxinA Combination 5EXPERIMENTALParticipants will receive a single treatment of co-reconstituted trenibotulinumtoxinE and onabotulinumtoxinA.
TrenibotulinumtoxinE/OnabotulinumtoxinA Combination 6EXPERIMENTALParticipants will receive a single treatment of co-reconstituted trenibotulinumtoxinE and onabotulinumtoxinA.
TrenibotulinumtoxinE/OnabotulinumtoxinA Combination 7EXPERIMENTALParticipants will receive a single treatment of co-reconstituted trenibotulinumtoxinE and onabotulinumtoxinA.
TrenibotulinumtoxinE/OnabotulinumtoxinA Combination 8EXPERIMENTALParticipants will receive a single treatment of co-reconstituted trenibotulinumtoxinE and onabotulinumtoxinA.
OnabotulinumtoxinAACTIVE_COMPARATORParticipants will receive a single treatment of onabotulinumtoxinA.
PlaceboPLACEBO_COMPARATORParticipants will receive a single treatment of placebo.

Interventions

NameTypeDescription
TrenibotulinumtoxinE and OnabotulinumtoxinADRUGInjection
PlaceboDRUGInjection
OnabotulinumtoxinADRUGInjection
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * For glabellar lines (GL) indication: participant must have moderate or severe GL at maximum furrow as assessed by both the investigator and participant using the AGLSS at Screening and Baseline (Day 1) visits. * Participant must be in good health as per investigator's judgment...

Countries:United States
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWOct 13, 2026NCT07871513NEW_TRIAL: changed
LOWOct 13, 2026NCT07871513NEW_TRIAL: changed

Explore more on BiopharmaWatch

AbbVie Inc. (ABBV)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with TCompanies A to ZEvery biotech and pharma company we track